Hanall Biopharma Co., Ltd. (KRX: 009420)
South Korea
· Delayed Price · Currency is KRW 31,850
-800 (-2.45%)
Dec 20, 2024, 3:30 PM KST
Hanall Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 134,245 | 134,910 | 109,995 | 101,594 | 88,602 | 108,452 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 134,245 | 134,910 | 109,995 | 101,594 | 88,602 | 108,452 | Upgrade
|
| Revenue Growth (YoY) | 0.70% | 22.65% | 8.27% | 14.66% | -18.30% | 18.09% | Upgrade
|
| Cost of Revenue | 65,364 | 59,870 | 48,120 | 41,364 | 38,027 | 45,771 | Upgrade
|
| Gross Profit | 68,880 | 75,040 | 61,876 | 60,231 | 50,575 | 62,681 | Upgrade
|
| Selling, General & Admin | 51,151 | 47,520 | 42,586 | 38,472 | 34,264 | 34,114 | Upgrade
|
| Research & Development | 23,280 | 23,945 | 16,498 | 10,462 | 9,316 | 10,051 | Upgrade
|
| Other Operating Expenses | 650.99 | 669.45 | 584.09 | 605.75 | 541.03 | 605.07 | Upgrade
|
| Operating Expenses | 75,808 | 73,296 | 60,370 | 50,132 | 44,640 | 45,591 | Upgrade
|
| Operating Income | -6,928 | 1,743 | 1,506 | 10,099 | 5,935 | 17,090 | Upgrade
|
| Interest Expense | -70.75 | -63.86 | -21.88 | -25.48 | -16.01 | -13.75 | Upgrade
|
| Interest & Investment Income | 696.6 | 1,227 | 1,427 | 719.84 | 2,145 | 2,142 | Upgrade
|
| Earnings From Equity Investments | -162.64 | -62.12 | -45.39 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -140.58 | 349.6 | -600.15 | -115.94 | 82.78 | 281.27 | Upgrade
|
| Other Non Operating Income (Expenses) | -622.91 | -1,067 | -228.48 | -745.87 | 11,138 | 213.68 | Upgrade
|
| EBT Excluding Unusual Items | -7,228 | 2,127 | 2,037 | 9,932 | 19,284 | 19,713 | Upgrade
|
| Gain (Loss) on Sale of Investments | 490.59 | 1,121 | -124.34 | -177.44 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -456.78 | -9.32 | 16.99 | -1,052 | -14.29 | 9.34 | Upgrade
|
| Asset Writedown | -27.61 | -36.72 | - | - | -44.82 | -2,267 | Upgrade
|
| Pretax Income | -7,222 | 3,203 | 1,929 | 8,702 | 19,225 | 17,455 | Upgrade
|
| Income Tax Expense | -933.83 | -306.08 | 1,678 | -194.05 | -539.21 | -1,719 | Upgrade
|
| Net Income | -6,288 | 3,509 | 251.47 | 8,896 | 19,765 | 19,174 | Upgrade
|
| Net Income to Common | -6,288 | 3,509 | 251.47 | 8,896 | 19,765 | 19,174 | Upgrade
|
| Net Income Growth | - | 1295.23% | -97.17% | -54.99% | 3.08% | 481.02% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Change (YoY) | 0.02% | -0.24% | -0.76% | 0.05% | 0.00% | - | Upgrade
|
| EPS (Basic) | -124.03 | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | Upgrade
|
| EPS (Diluted) | -124.78 | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | Upgrade
|
| EPS Growth | - | 1298.63% | -97.15% | -55.01% | 3.08% | 481.02% | Upgrade
|
| Free Cash Flow | 7,072 | 27,231 | 22,434 | -3,766 | -1,633 | 18,368 | Upgrade
|
| Free Cash Flow Per Share | 139.48 | 537.18 | 441.48 | -73.55 | -31.91 | 358.92 | Upgrade
|
| Gross Margin | 51.31% | 55.62% | 56.25% | 59.29% | 57.08% | 57.80% | Upgrade
|
| Operating Margin | -5.16% | 1.29% | 1.37% | 9.94% | 6.70% | 15.76% | Upgrade
|
| Profit Margin | -4.68% | 2.60% | 0.23% | 8.76% | 22.31% | 17.68% | Upgrade
|
| Free Cash Flow Margin | 5.27% | 20.18% | 20.40% | -3.71% | -1.84% | 16.94% | Upgrade
|
| EBITDA | -3,858 | 4,990 | 4,558 | 12,824 | 8,829 | 19,805 | Upgrade
|
| EBITDA Margin | -2.87% | 3.70% | 4.14% | 12.62% | 9.97% | 18.26% | Upgrade
|
| D&A For EBITDA | 3,070 | 3,247 | 3,053 | 2,725 | 2,894 | 2,715 | Upgrade
|
| EBIT | -6,928 | 1,743 | 1,506 | 10,099 | 5,935 | 17,090 | Upgrade
|
| EBIT Margin | -5.16% | 1.29% | 1.37% | 9.94% | 6.70% | 15.76% | Upgrade
|
| Effective Tax Rate | - | - | 86.97% | - | - | - | Upgrade
|
| Advertising Expenses | - | 3,287 | 3,090 | 2,112 | 1,889 | 1,579 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.